Marksans Pharma Limited (MARKSANS) Share Price
NSE · Healthcare · Drug Manufacturers - General · ISIN INE750C01026
Key metrics
- Market Cap
- ₹14,610 Cr
- P/E Ratio
- 28.26
- EPS
- 11.38
- Book Value
- 67.36
- P/B Ratio
- 4.79
- ROE
- 13.69%
- ROCE
- 15.17%
- Debt / Equity
- 0.11
- Net Margin
- 14.21%
- Revenue Growth
- 12.52%
- Profit Growth
- 9.81%
- Dividend Yield
- 0.28%
- 52W High
- ₹345.50
- 52W Low
- ₹155.00
- Market Cap Band
- mid cap
- Face Value
- 1
Ratios computed from the annual results period ending 2026-03-31.
About Marksans Pharma Limited
Marksans Pharma Limited, together with its subsidiaries, engages in the research, manufacturing, marketing, and sale of pharmaceutical formulations in the United States, North America, Europe, the United Kingdom, Australia, New Zealand, and internationally. The company offers products in the pain management, cardiovascular, central nervous system, anti-diabetic, gastrointestinal, analgesics, upper respiratory, ear care, skincare, anticancer, anti-ulcerative, anti-allergy, antiviral, dietary, cardiac, dermatology, antihistamines, anti-fungal, anti-viral, laxatives, and cold and cough therapeutic areas. Its product portfolio includes plain, enteric-coated, and film coated tablets; soft gelatin and hard capsules; oral liquids; and ointments, as well as creams and liquids. The company provides its products to supermarkets, high street retailers, pharmacy chains, and wholesalers. Marksans Pharma Limited was incorporated in 1992 and is headquartered in Mumbai, India.
- Headquarters
- Mumbai, India
- Employees
- 1,685
- Promoter Holding
- 43.87%
The full Marksans Pharma Limited analysis
Create a free account to open the complete MARKSANS deep-dive — fourteen tabs of fundamental, technical, institutional and ownership data.
- 10-year financialsIncome statement, balance sheet and cash flow, year by year.
- Valuation & fair valueFair-value estimates, quality scores and a value grade.
- Charts & technicalsCandlestick charts, RSI, MACD, Supertrend and detected patterns.
- Shareholding historyPromoter, FII, DII and public holdings across every quarter.
- Ace investor holdingsWhich well-known investors hold it, and how their stake changed.
- Deals & insider tradesBulk and block deals, insider transactions and mutual-fund holdings.